Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042497
Status:
SUSPENDED
Last Update Posted:
2005-06-24
First Post:
2002-07-30
Brief Title:
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
Sponsor:
Anosys
Organization:
Anosys
Study Overview
Official Title:
A Phase II Multicenter Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
Status:
SUSPENDED
Status Verified Date:
2002-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None